164 related articles for article (PubMed ID: 37325938)
1. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study.
Dai X; Tao L; Wang J; Wu W; Bian W; Dai X; Chen S
Cancer Med; 2023 Aug; 12(15):16108-16118. PubMed ID: 37325938
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Huang J; Xu B; Liu Y; Huang J; Lu P; Ba Y; Wu L; Bai Y; Zhang S; Feng J; Cheng Y; Li J; Wen L; Yuan X; Ma C; Hu C; Fan Q; Wang X
Cancer Commun (Lond); 2019 Apr; 39(1):16. PubMed ID: 30940189
[TBL] [Abstract][Full Text] [Related]
3. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
Zhao W; Ke S; Cai X; Zuo Z; Shi W; Qiu H; Cai G; Gong Y; Wu Y; Ruan S; Chen Y
Radiother Oncol; 2023 Jul; 184():109679. PubMed ID: 37105302
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer.
Liu M; Jia Q; Wang X; Sun C; Yang J; Chen Y; Li Y; Min L; Zhang X; Zhu C; Gubat JA; Chen Y
Anticancer Drugs; 2020 Apr; 31(4):403-410. PubMed ID: 31917701
[TBL] [Abstract][Full Text] [Related]
6. Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study.
Hu Z; Sun S; Zhao X; Yu H; Wu X; Wang J; Chang J; Wang H
Oncologist; 2022 Apr; 27(4):253-e312. PubMed ID: 35380726
[TBL] [Abstract][Full Text] [Related]
7. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Chemotherapy for Metastatic Esophageal Cancer in a Community Hospital in Brazil.
Victor CR; Fujiki FK; Takeda FR; Hoff PMG; de Castria TB
J Glob Oncol; 2019 Jul; 5():1-10. PubMed ID: 31365299
[TBL] [Abstract][Full Text] [Related]
9. Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial.
Cheng K; Zhou YW; Chen Y; Li ZP; Qiu M; Liu JY
Cancer Control; 2022; 29():10732748221080332. PubMed ID: 35343258
[TBL] [Abstract][Full Text] [Related]
10. PD-1 inhibitor monotherapy versus combination therapy: A real-world study of patients with recurrent or metastatic advanced esophageal squamous cell carcinoma after first-line chemotherapy.
Yang G; Sun H; Zhou C; Sun N; Xu L; Huang W; Li B
J Cancer Res Ther; 2022 Apr; 18(2):545-552. PubMed ID: 35645126
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
Cao Y; Qin S; Luo S; Li Z; Cheng Y; Fan Y; Sun Y; Yin X; Yuan X; Li W; Liu T; Hsu CH; Lin X; Kim SB; Kojima T; Zhang J; Lee SH; Bai Y; Muro K; Doi T; Bai C; Gu K; Pan HM; Bai L; Yang JW; Cui Y; Lu W; Chen J
ESMO Open; 2022 Feb; 7(1):100341. PubMed ID: 34973513
[TBL] [Abstract][Full Text] [Related]
13. SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study.
Mu L; Song Y; Zhao K; Liu Y; Fan Q; Wang X; Li Q; Wang X; Huang J
Thorac Cancer; 2021 May; 12(9):1373-1381. PubMed ID: 33760397
[TBL] [Abstract][Full Text] [Related]
14. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
15. Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.
Randrian V; Adenis A; Desrame J; Barbier E; Di Fiore F; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Breysacher G; Roquin G; Louafi S; Lopez A; Louvet C; Borg C; Metges JP; Faroux R; Gaba L; Manfredi S; Tougeron D
Dig Liver Dis; 2020 Mar; 52(3):347-350. PubMed ID: 31899122
[TBL] [Abstract][Full Text] [Related]
16. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
17. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
18. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.
Liu C; Sun H; Huang W; Wang Z; Fu C; Han D; Zhao Q; Wu X; Li B
Front Immunol; 2023; 14():1193394. PubMed ID: 37325650
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma.
Zhao Z; Yin MM; Zhao WF; Wang CJ
Medicine (Baltimore); 2023 Aug; 102(33):e34794. PubMed ID: 37603519
[TBL] [Abstract][Full Text] [Related]
20. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen L; Kato K; Kim SB; Ajani JA; Zhao K; He Z; Yu X; Shu Y; Luo Q; Wang J; Chen Z; Niu Z; Zhang L; Yi T; Sun JM; Chen J; Yu G; Lin CY; Hara H; Bi Q; Satoh T; Pazo-Cid R; Arkenau HT; Borg C; Lordick F; Li L; Ding N; Tao A; Shi J; Van Cutsem E;
J Clin Oncol; 2022 Sep; 40(26):3065-3076. PubMed ID: 35442766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
